Weight Loss Peptides
FDA-approved and research peptides studied for weight management and metabolic health.
About Weight Loss Peptides
Weight loss peptides include some of the most significant pharmaceutical developments in recent years. GLP-1 receptor agonists like Semaglutide (Wegovy/Ozempic) and Tirzepatide (Mounjaro/Zepbound) are FDA-approved medications that have demonstrated impressive results in clinical trials. These peptides work by mimicking natural hormones that regulate appetite, blood sugar, and metabolism. Research continues on next-generation compounds like Retatrutide, which targets multiple metabolic pathways.
All Weight Loss Peptides (15)
Semaglutide
FDA ApprovedAlso: Ozempic, Wegovy
A GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.
Tirzepatide
FDA ApprovedAlso: Mounjaro, Zepbound
A dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.
AOD-9604
Clinical TrialsAlso: Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191
A modified fragment of human growth hormone (amino acids 177-191) studied for fat metabolism effects without the broader hormonal effects of full GH.
Retatrutide
Clinical TrialsAlso: LY3437943, Triple G
A triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. Expected FDA approval late 2026 to early 2027.
HGH Fragment 176-191
Clinical TrialsAlso: Frag 176-191, HGH Frag
The lipolytic fragment of human growth hormone. Contains the fat-burning portion of HGH without effects on blood sugar or cell proliferation.
Liraglutide
FDA ApprovedAlso: Victoza, Saxenda
An FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing.
Dulaglutide
FDA ApprovedAlso: Trulicity
An FDA-approved weekly GLP-1 receptor agonist for type 2 diabetes. Fused to an Fc antibody fragment for extended duration of action.
Exenatide
FDA ApprovedAlso: Byetta, Bydureon
The first GLP-1 receptor agonist approved for diabetes. Derived from Gila monster saliva. Available in twice-daily and weekly formulations.
Survodutide
Clinical TrialsAlso: BI 456906
A dual GLP-1/glucagon receptor agonist in development for obesity and MASH. Has FDA Breakthrough Therapy Designation for MASH with fibrosis.
Orforglipron
Clinical TrialsAlso: LY3502970, OWL833
An oral non-peptide GLP-1 receptor agonist. NDA under FDA review with decision expected April 10, 2026. If approved, will compete directly with oral Wegovy.
Semaglutide Oral
FDA ApprovedAlso: Rybelsus
The oral formulation of semaglutide using SNAC absorption enhancer. First oral GLP-1 receptor agonist FDA approved.
Setmelanotide
FDA ApprovedAlso: Imcivree, RM-493
An MC4R agonist for rare genetic obesity disorders. FDA approved for specific gene mutations causing obesity.
CagriSema
Clinical TrialsAlso: Semaglutide + Cagrilintide
A combination of semaglutide and cagrilintide (amylin analog). The most effective weight loss drug candidate, showing 22.7% body weight reduction in Phase 3 trials - superior to any single-agent GLP-1.
5-Amino-1MQ
PreclinicalAlso: 5-amino-1-methylquinolinium, NNMT Inhibitor
A selective NNMT (nicotinamide N-methyltransferase) inhibitor that enhances cellular energy metabolism. Not a peptide but a small molecule research compound commonly used alongside peptides for fat loss and metabolic support.
Cagrilintide
Clinical TrialsAlso: AM833, NN9838
A long-acting amylin analog developed by Novo Nordisk for obesity treatment. Works through a different mechanism than GLP-1 agonists, targeting amylin receptors in the brain to reduce appetite and slow gastric emptying. Shows enhanced weight loss when combined with semaglutide (CagriSema).
Frequently Asked Questions About Weight Loss Peptides
What are the best peptides for weight loss?
The most effective weight loss peptides with FDA approval include Semaglutide (Wegovy) and Tirzepatide (Zepbound). Clinical trials have shown average weight loss of 15-25% body weight with these medications when combined with lifestyle modifications.
How do GLP-1 peptides work for weight loss?
GLP-1 peptides like Semaglutide mimic the glucagon-like peptide-1 hormone, which slows gastric emptying, increases insulin secretion, reduces glucagon release, and acts on brain appetite centers to reduce hunger and increase satiety.
Are weight loss peptides safe?
FDA-approved weight loss peptides like Semaglutide and Tirzepatide have undergone extensive clinical trials. Common side effects include GI symptoms like nausea. They carry important warnings and should only be used under medical supervision.